BMI View: This quarter has seen the extension of GlaxoSmithKline's bribery allegation investigations.
These now span the Gulf Levant, bringing Jordan's pharmaceutical industry into the spotlight. We do not
believe Jordan will attract interest from innovative drugmaker ..."
BMI View: Jordan is a moderately attractive pharmaceutical market in the Middle East and Africa (MEA)
region. However, despite a number of positive factors, we highlight current cutbacks in government
spending, which have directly impacted the pharmaceutical market (m ..."
BMI View: We continue to view Jordan as a moderately attractive prospect for pharmaceutical companies.
Despite its relatively well-developed healthcare system, the country is focused on the use of generic
medicines, many of which are produced locally. Nevertheless, ov ..."
BMI View: As we anticipated, Jordanian pharmaceutical exports increased in 2012 due to base effects
around the Arab Spring in 2011. We project exports from Jordan will slow through to 2017 as generic
competition from Indian and Chinese drugmakers increases, and as multinational ..."
BMI View: Although Jordan's pharmaceutical market is not as attractive as those of Israel and Lebanon in the Gulf Levant, we are broadly positive in our outlook for the sector where consumption is set to increase due to the growing population, increased urbanisation and incidence ..."
We expect that Jordan will continue to provide modest opportunities to research-based pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance coverage , we envisage measures aiming to promote the use of cheaper generic medicines, in tand ..."
BMI View: We expect that Jordan will continue to provide modest opportunities to research-based
pharmaceutical manufacturers. In line with the authorities' efforts to expand healthcare insurance
coverage, we envisage measures aiming to promote the use of cheaper generic medicin ..."